Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effect of Oxybutynin on Opioid Use After Urologic Surgery in Children

14. november 2026 opdateret af: Bryce Weber, University of Calgary

A Randomized Double-Blind Placebo-Controlled Trial Evaluating the Opioid-Sparing Effect of Preoperative Oxybutynin in Children Undergoing Urologic Reconstruction

The goal of this clinical trial is to determine whether giving oxybutynin before urologic reconstruction surgery reduces the amount of opioid pain medication needed in children. Oxybutynin is a medication that helps reduce bladder spasms, which can cause pain and discomfort after surgery.

The main question this study aims to answer is:

Does giving oxybutynin before surgery reduce the amount of opioid pain medication children need during the first 6 hours after surgery?

Researchers will compare oxybutynin with a placebo (a tablet containing no active medication) to see whether oxybutynin reduces opioid use after surgery.

Studieoversigt

Status

Ikke rekrutterer endnu

Detaljeret beskrivelse

Background

Children undergoing pediatric urologic reconstruction, such as pyeloplasty and hypospadias repair, frequently require urinary drainage via ureteral stent and/or urethral catheter. These tools cause the bladder to contract involuntarily, mediated by muscarinic receptors (i.e., bladder spasms). This leads to increased catheter-related bladder discomfort (CRBD), bladder spasm-associated pain and postoperative opioid use.

Oxybutynin, an antimuscarinic agent, reduces the occurrence of bladder spasms and thus the number and severity of CRBD events and bladder spasm-related pain. This reduction in discomfort/pain may contribute to decreased postoperative opioid use, as suggested by retrospective pediatric data.

Postoperative management of urologic reconstruction surgeries includes PRN administration of opioids and oxybutynin to treat bladder spasm-related discomfort/pain according to institutional practice and prior pediatric urology literature. Oxybutynin takes 1 hour to reach its maximal plasma concentration, during which time significant bladder spasm-related symptoms may already be present when the child is awake. However, opioids such as morphine achieve their maximal effects within 10 minutes. Because opioids are much faster-acting than oxybutynin, this may increase the likelihood of concomitant administration when the child is awake with discomfort/pain. We are therefore considering using oxybutynin preoperatively, rather than just postoperatively PRN, since its plasma concentration will already be maximal or near-maximal upon waking, which may lead to less CRBD, bladder spasm-related pain, and postoperative opioid use.

This study aims to reduce the use of opioids to treat pediatric patients undergoing urologic reconstruction. Opioids carry significant side effects that include nausea, vomiting, respiratory depression, addiction, urinary retention, tolerance, and constipation. Combined with the ongoing opioid epidemic, there is an increased effort among caregivers, including nurses and physicians, to find other means to reduce pain in pediatric patients.

Opioid therapy has also been shown not to be effective in treating bladder spasm-related symptoms (e.g., CRBD, bladder spasm-related pain). As opposed to opioids, oxybutynin directly targets bladder spasm-associated symptoms, and may reduce the severity of side effects. Side effects of oxybutynin include dry mouth, constipation, dizziness, urinary retention, and blurry vision.

Emerging pediatric urology data suggest that a single preoperative dose may reduce early postoperative opioid requirements. However, current evidence is retrospective and non-randomized. There is no high-quality randomized pediatric study evaluating the opioid sparing effects of preoperative oxybutynin administration in pediatric patients undergoing urologic reconstruction.

Study Need, Importance, and Hypothesis

Urologic reconstruction surgeries requiring a stent and/or catheter can be associated with significant CRBD, bladder-spasm associated pain and morbidity. With the growing recognition of the need to decrease opioid medication, our primary objective is to assess whether the administration of preoperative oxybutynin reduces opioid use. We hypothesize that preoperative oxybutynin reduces early postoperative opioid use in children undergoing pyeloplasty or hypospadias repair.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

200

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Alberta
      • Calgary, Alberta, Canada, T2B6A8
        • Alberta Children's Hospital
        • Ledende efterforsker:
          • Bryce Weber
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

Ikke ældre end 17 år (Barn)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • All children aged 0 to 17 years old admitted for pyeloplasty or hypospadias repair. There is no minimum weight for inclusion

Exclusion Criteria:

  • Contraindications to anticholinergic medications
  • Urinary retention disorders
  • Gastrointestinal obstruction/ileus
  • Contraindications to anesthetic protocol, including 1) allergy to any anesthetic medication in protocol, 2) refusal of regional technique, 3) contraindications to ketorolac (i.e., recent GI bleed, recent intracranial bleed, renal dysfunction, acute kidney injury)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Preoperative Oxybutynin

Participants will receive oxybutynin 0.2 mg/kg (to a maximum dose of 5 mg), orally administered by the day surgery nurse in the day surgery holding area prior to surgery.

Participants will receive oxybutynin 0.2 mg/kg (to a maximum dose of 5 mg), orally administered by the day surgery nurse in the day surgery holding area prior to surgery.

Placebo komparator: Preoperative Placebo

Participants will receive a matching placebo tablet, orally administered by the day surgery nurse in the day surgery holding area prior to surgery.

Participants will receive a matching placebo tablet, orally administered by the day surgery nurse in the day surgery holding area prior to surgery.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Total Cumulative Postoperative Opioid Consumption (MME/kg)
Tidsramme: From the end of surgery through 6 hours postoperatively

Total cumulative morphine milligram equivalents per kilogram (MME/kg) administered within 6 hours after surgery

From the end of surgery through 6 hours postoperatively

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of Participants Receiving Postoperative Opioids
Tidsramme: From the end of surgery through 6 hours postoperatively

Whether any opioid medication was administered within 6 hours after surgery (yes/no)

From the end of surgery through 6 hours postoperatively
Postoperative Pain Scores (NRS/FLACC)
Tidsramme: At 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, and 6 hours following postoperative removal of the laryngeal mask airway or endotracheal tube

Pain assessed using age-appropriate validated scales: the Numeric Rating Scale (NRS; 0-10) or the Face, Legs, Activity, Cry, Consolability (FLACC; 0-10) scale. Higher scores indicate greater pain.

At 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, and 6 hours following postoperative removal of the laryngeal mask airway or endotracheal tube
Proportion of Participants Receiving Postoperative Rescue Oxybutynin
Tidsramme: From the end of surgery through 6 hours postoperatively

Whether oxybutynin was administered as needed (PRN) within 6 hours after surgery (yes/no).

From the end of surgery through 6 hours postoperatively
Total Cumulative Postoperative Oxybutynin Consumption (mg/kg)
Tidsramme: From the end of surgery through 6 hours postoperatively

Total cumulative dose of oxybutynin administered per kilogram of body weight during the first 6 hours after surgery.

From the end of surgery through 6 hours postoperatively
Incidence of Adverse Events
Tidsramme: From preoperative study medication administration through postoperative discharge

Occurrence of adverse events, including dry mouth, flushing, tachycardia, agitation, sedation, and urinary retention.

From preoperative study medication administration through postoperative discharge

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. november 2026

Primær færdiggørelse (Anslået)

1. november 2028

Studieafslutning (Anslået)

1. november 2028

Datoer for studieregistrering

Først indsendt

23. oktober 2026

Først indsendt, der opfyldte QC-kriterier

29. oktober 2026

Først opslået (Faktiske)

2. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

14. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner